Results of Neuromarker Studies in Patients with Type 2 Diabetes Mellitus on Programmed Hemodialysis

Abstract

The aim was to study the blood levels of brain neurotrophic factor BDNF, neuron–specific enolase NSE and protein S100 β in patients with type 2 diabetes mellitus complicated by chronic kidney disease and receiving programmed hemodialysis.

Material and methods of research: We examined and examined a total of 90 patients suffering from type 2 diabetes mellitus, with CKD V art. on programmed hemodialysis. Of these, there were 37 women and 53 men.  The average age of men was 68 ± 4.2 years, and the average age of women was 64 ± 5.6 years.

All 90 patients underwent all studies, including general clinical biochemical, hormonal blood tests, BDNF in the blood ultrasound of internal organs, dopplerography of the main arteries of the head, consultations of narrow specialists. We assessed the quality of life of patients before hemodialysis and in the dynamics of treatment using the WHO Short Questionnaire on Quality of Life Assessment (WHOQOL-BREF) and the Hamilton Depression Scale.

Results and discussion.    According to our studies, serum levels of BDNF in groups of patients with type 2 diabetes significantly increase in comparison with the control group as the degree of CHEM increases.

In all groups, significant differences in the content of NSE in the blood (p < 0.05) were found in comparison with the control: the values tended to increase with increasing degree of CHEM. 

In group 1, there was no significant difference in the content of S100B in the blood compared with the control (p >0.05), while in groups 2 and 3, these differences were significantly significant.: S100B was significantly higher in these patients.

Conclusions Our studies have shown that in patients with type 2 diabetes with DN and CKD V art.    there is an increase in the concentration of BDNF, S100B, NSE in the blood, which indicates the need for preventive measures to aggravate neurological deficits in order to prevent the development of cerebrovascular disorders.